Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 10/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192969 | 1.00 | HDAC1 (0.61) | HDAC1HDAC2BRD4AURKAXDH | |
| SCHEMBL27570011 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2BRD4AURKABRPF1 | |
| SCHEMBL3298684 | 0.82 | BRD4 (0.56) | HDAC1HDAC2BRD4AURKAHTT | |
| SCHEMBL5194370 | 0.81 | XDH (0.53) | HDAC1HDAC2AURKAXDHSMN1; SMN2 | |
| SCHEMBL6435213 | 0.81 | XDH (0.46) | HDAC1HDAC2BRD4AURKAXDH | |
| SCHEMBL7052321 | 0.81 | XDH (0.61) | HDAC1HDAC2BRD4AURKAXDH | |
| SCHEMBL5193809 | 0.81 | XDH (0.61) | HDAC1HDAC2BRD4AURKAXDH | |
| SCHEMBL28828155 | 0.79 | BRD4 (0.59) | HDAC1HDAC2BRD4HTTSMN1; SMN2 | |
| SCHEMBL2623138 | 0.79 | XDH (0.62) | HDAC1HDAC2BRD4AURKAXDH | |
| SCHEMBL38663949 | 0.78 | BRD4 (0.58) | HDAC1HDAC2BRD4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600044-B2 | Such as cis-(-)-4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone (lamivudine, 3TC) or emtricitabine via anomerization/transglycosylation | BRANTFORD CHEMICALS INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | disclosed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | HDAC1 2911/4885HDAC2 4302/4885BRD4 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.